Histone deacetylase inhibitors that target tubulin

Cancer Letters

Volumn 280, Issue 2, 2009, Pages 222-232

  Schemies, Jörg ^a   Sippl, Wolfgang ^b   Jung, Manfred ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Epigenetics; HDAC6; Histone deacetylases; Sirtuin; Tubulin

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; ARISTOFORIN; BORTEZOMIB; CAMBINOL; EX 527; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NF 675; NICOTINAMIDE; NILTUBACIN; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; SALERMIDE; SIRTINOL; SIRTUIN 1; SIRTUIN 2; SPLITOMICIN DERIVATIVE; TENOVIN 6; TENOVIN DERIVATIVE; TRAPOXIN B; TRICHOSTATIN A; TRIPOS 360702; TUBACIN; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; BURKITT LYMPHOMA; CANCER INHIBITION; CYTOTOXICITY; DRUG IDENTIFICATION; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HUMAN; IC 50; LUNG CARCINOMA; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 67349232749     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.01.040     Document Type: Review

References (69)

1. Wolffe A.P., and Matzke M.A. Epigenetics: regulation through repression. Science 286 (1999) 481-486
2. Biel M., Wascholowski V., and Giannis A. Epigenetics - an epicenter of gene regulation: histones and histone-modifying enzymes. Angew. Chem., Int. Ed. Engl. 44 (2005) 3186-3216
3. Schafer S., and Jung M. Chromatin modifications as targets for new anticancer drugs. Arch. Pharm. (Weinheim) 338 (2005) 347-357
4. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
5. Santos-Rosa H., and Caldas C. Chromatin modifier enzymes. The histone code and cancer. Eur. J. Cancer 41 (2005) 2381-2402
6. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 389 (1997) 349-352
7. North B.J., and Verdin E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol. 5 (2004) 224
8. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., Yoshida M., Wang X.F., and Yao T.P. HDAC6 is a microtubule-associated deacetylase. Nature 417 (2002) 455-458
9. Matsuyama A., Shimazu T., Sumida Y., Saito A., Yoshimatsu Y., Seigneurin-Berny D., Osada H., Komatsu Y., Nishino N., Khochbin S., Horinouchi S., and Yoshida M. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 21 (2002) 6820-6831
10. Zhang Y., Li N., Caron C., Matthias G., Hess D., Khochbin S., and Matthias P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 22 (2003) 1168-1179
11. +-dependent tubulin deacetylase. Mol. Cell 11 (2003) 437-444
12. Honore S., Pasquier E., and Braguer D. Understanding microtubule dynamics for improved cancer therapy. Cell. Mol. Life Sci. 62 (2005) 3039-3056
13. Pellegrini F., and Budman D.R. Review: tubulin function. Action of antitubulin drugs, and new drug development. Cancer Invest. 23 (2005) 264-273
14. Boyault C., Zhang Y., Fritah S., Caron C., Gilquin B., Kwon S.H., Garrido C., Yao T.P., Vourc'h C., Matthias P., and Khochbin S. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev. 21 (2007) 2172-2181
15. Hideshima T., Bradner J.E., Wong J., Chauhan D., Richardson P., Schreiber S.L., and Anderson K.C. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl. Acad. Sci. USA 102 (2005) 8567-8572
16. Emanuele S., Lauricella M., Carlisi D., Vassallo B., DAnneo A., Di Fazio P., Vento R., and Tesoriere G. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 12 (2007) 1327-1338
17. Lee Y.S., Lim K.H., Guo X., Kawaguchi Y., Gao Y., Barrientos T., Ordentlich P., Wang X.F., Counter C.M., and Yao T.P. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res. 68 (2008) 7561-7569
18. Fiskus W., Rao R., Fernandez P., Herger B., Yang Y., Chen J., Kolhe R., Mandawat A., Wang Y., Joshi R., Eaton K., Lee P., Atadja P., Peiper S., and Bhalla K. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood 112 (2008) 2896-2905
19. Pandey U.B., Nie Z., Batlevi Y., McCray B.A., Ritson G.P., Nedelsky N.B., Schwartz S.L., DiProspero N.A., Knight M.A., Schuldiner O., Padmanabhan R., Hild M., Berry D.L., Garza D., Hubbert C.C., Yao T.P., Baehrecke E.H., and Taylor J.P. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447 (2007) 859-863
20. Pallos J., Bodai L., Lukacsovich T., Purcell J.M., Steffan J.S., Thompson L.M., and Marsh J.L. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. (2008) 10.1093/hmg/ddn1273
21. Richon V.M., Webb Y., Merger R., Sheppard T., Jursic B., Ngo L., Civoli F., Breslow R., Rifkind R.A., and Marks P.A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA 93 (1996) 5705-5708
22. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., and Marks P.A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA 95 (1998) 3003-3007
23. Breslow R., Belvedere S., and Gershell L. Development of cytodifferentiating agents for cancer chemotherapy. Helv. Chim. Acta 83 (2000) 1685-1692
24. Itazaki H., Nagashima K., Sugita K., Yoshida H., Kawamura Y., Yasuda Y., Matsumoto K., Ishii K., Uotani N., Nakai H., et al. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J. Antibiot. (Tokyo) 43 (1990) 1524-1532
25. Yoshida M., Horinouchi S., and Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 17 (1995) 423-430
26. Suzuki T., Ando T., Tsuchiya K., Fukazawa N., Saito A., Mariko Y., Yamashita T., and Nakanishi O. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. 42 (1999) 3001-3003
27. Haggarty S.J., Koeller K.M., Wong J.C., Butcher R.A., and Schreiber S.L. Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem. Biol. 10 (2003) 383-396
28. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., and Schreiber S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 100 (2003) 4389-4394
29. Hildmann C., Wegener D., Riester D., Hempel R., Schober A., Merana J., Giurato L., Guccione S., Nielsen T.K., Ficner R., and Schwienhorst A. Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases. J. Biotechnol. 124 (2006) 258-270
30. Chen Y., Lopez-Sanchez M., Savoy D.N., Billadeau D.D., Dow G.S., and Kozikowski A.P. A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. J. Med. Chem. 51 (2008) 3437-3448
31. Kozikowski A.P., Tapadar S., Luchini D.N., Kim K.H., and Billadeau D.D. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J. Med. Chem. 51 (2008) 4370-4373
32. Wittich S., Scherf H., Xie C., Brosch G., Loidl P., Gerhauser C., and Jung M. Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in friend leukemic cells. J. Med. Chem. 45 (2002) 3296-3309
33. Wittich S., Scherf H., Xie C., Heltweg B., Dequiedt F., Verdin E., Gerhauser C., and Jung M. Effect of inhibitors of histone deacetylase on the induction of cell differentiation in murine and human erythroleukemia cell lines. Anticancer Drugs 16 (2005) 635-643
34. Schafer S., Saunders L., Eliseeva E., Velena A., Jung M., Schwienhorst A., Strasser A., Dickmanns A., Ficner R., Schlimme S., Sippl W., and Verdin E. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Bioorg. Med. Chem. 16 (2008) 2011-2033
35. Schäfer S., Saunders L., Schlimme S., Valkov V., Wagner J.M., Kratz F., Sippl W., Verdin E., and Jung M. Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors. Chem. Med. Chem. 4 (2009) 283-290
36. Scott G.K., Marx C., Berger C.E., Saunders L.R., Verdin E., Schäfer S., Jung M., and Benz C.C. Destabilization of ERBB2 transcripts by targeting 3' UTR mRNA associated HuR and histone deacetylase-6 (HDAC6). Mol. Cancer Res. 6 (2008) 1250-1258
37. Itoh Y., Suzuki T., Kouketsu A., Suzuki N., Maeda S., Yoshida M., Nakagawa H., and Miyata N. Design, synthesis, structure-selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. J. Med. Chem. 50 (2007) 5425-5438
38. Suzuki T., Kouketsu A., Itoh Y., Hisakawa S., Maeda S., Yoshida M., Nakagawa H., and Miyata N. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J. Med. Chem. 49 (2006) 4809-4812
39. Heltweg B., Dequiedt F., Marshall B.L., Brauch C., Yoshida M., Nishino N., Verdin E., and Jung M. Subtype selective substrates for histone deacetylases. J. Med. Chem. 47 (2004) 5235-5243
40. Schiff P.B., Fant J., and Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 277 (1979) 665-667
41. Marcus A.I., Zhou J., O'Brate A., Hamel E., Wong J., Nivens M., El-Naggar A., Yao T.P., Khuri F.R., and Giannakakou P. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res. 65 (2005) 3883-3893
42. Saji S., Kawakami M., Hayashi S., Yoshida N., Hirose M., Horiguchi S., Itoh A., Funata N., Schreiber S.L., Yoshida M., and Toi M. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 24 (2005) 4531-4539
43. Grant S., Easley C., and Kirkpatrick P. Vorinostat. Nat. Rev. Drug Discov. 6 (2007) 21-22
44. Taylor D.M., Maxwell M.M., Luthi-Carter R., and Kazantsev A.G. Biological and potential therapeutic roles of sirtuin deacetylases. Cell. Mol. Life Sci. (2008) (epub ahead of print)
45. +-dependent histone deacetylases (sirtuins). Curr. Pharm. Des. 14 (2008) 562-573
46. Grozinger C.M., Chao E.D., Blackwell H.E., Moazed D., and Schreiber S.L. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 276 (2001) 38837-38843
47. Heltweg B., and Jung M. A microplate reader-based nonisotopic histone deacetylase activity assay. Anal. Biochem. 302 (2002) 175-183
48. Dai X., Hayashi K., Nozaki H., Cheng Y., and Zhao Y. Genetic and chemical analyses of the action mechanisms of sirtinol in Arabidopsis. Proc. Natl. Acad. Sci. USA 102 (2005) 3129-3134
49. McGovern S.L., Caselli E., Grigorieff N., and Shoichet B.K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45 (2002) 1712-1722
50. Lara E., Mai A., Calvanese V., Altucci L., Lopez-Nieva P., Martinez-Chantar M.L., Varela-Rey M., Rotili D., Nebbioso A., Ropero S., Montoya G., Oyarzabal J., Velasco S., Serrano M., Witt M., Villar-Garea A., Inhof A., Mato J.M., Esteller M., and Fraga M.F. Salermide, a sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene (2008)
51. Mai A., Massa S., Lavu S., Pezzi R., Simeoni S., Ragno R., Mariotti F.R., Chiani F., Camilloni G., and Sinclair D.A. Design, synthesis and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (sirtuin) inhibitors. J. Med. Chem. 48 (2005) 7789-7795
52. Heltweg B., Gatbonton T., Schuler A.D., Posakony J., Li H., Goehle S., Kollipara R., Depinho R.A., Gu Y., Simon J.A., and Bedalov A. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 66 (2006) 4368-4377
53. +-dependent histone deacetylases, from kinase to sirtuin inhibition. J. Med. Chem. 49 (2006) 7307-7316
54. Finnin M.S., Donigian J.R., and Pavletich N.P. Structure of the histone deacetylase SIRT2. Natl. Struct. Biol. 8 (2001) 621-625
55. Outeiro T.F., Kontopoulos E., Altmann S.M., Kufareva I., Strathearn K.E., Amore A.M., Volk C.B., Maxwell M.M., Rochet J.C., McLean P.J., Young A.B., Abagyan R., Feany M.B., Hyman B.T., and Kazantsev A.G. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317 (2007) 516-519
56. Lyall R.M., Zilberstein A., Gazit A., Gilon C., Levitzki A., and Schlessinger J. Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation. J. Biol. Chem. 264 (1989) 14503-14509
57. Bedalov A., Gatbonton T., Irvine W.P., Gottschling D.E., and Simon J.A. Identification of a small molecule inhibitor of Sir2p. Proc. Natl. Acad. Sci. USA 98 (2001) 15113-15118
58. Pagans S., Pedal A., North B.J., Kaehlcke K., Marshall B.L., Dorr A., Hetzer-Egger C., Henklein P., Frye R., McBurney M.W., Hruby H., Jung M., Verdin E., and Ott M. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol. 3 (2005) e41
59. Neugebauer R.C., Uchiechowska U., Meier R., Hruby H., Valkov V., Verdin E., Sippl W., and Jung M. Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. J. Med. Chem. 51 (2008) 1203-1213
60. +dependent histone deacetylases (sirtuins). Chem. Med. Chem. 2 (2007) 1419-1431
61. Napper A.D., Hixon J., McDonagh T., Keavey K., Pons J.F., Barker J., Yau W.T., Amouzegh P., Flegg A., Hamelin E., Thomas R.J., Kates M., Jones S., Navia M.A., Saunders J.O., DiStefano P.S., and Curtis R. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J. Med. Chem. 48 (2005) 8045-8054
62. Uciechowska U., Schemies J., Neugebauer R.C., Huda E.-M., Schmitt M.L., Meier R., Verdin E., Jung M., and Sippl W. Thiobarbiturates as Sirtuin inhibitors: virtual screening, free energy calculations and biological testing. Chem. Med. Chem. 3 (2008) 1965-1976
63. Lain S., Hollick J.J., Campbell J., Staples O.D., Higgins M., Aoubala M., McCarthy A., Appleyard V., Murray K.E., Baker L., Thompson A., Mathers J., Holland S.J., Stark M.J., Pass G., Woods J., Lane D.P., and Westwood N.J. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13 (2008) 454-463
64. Tervo A.J., Kyrylenko S., Niskanen P., Salminen A., Leppanen J., Nyronen T.H., Jarvinen T., and Poso A. An in silico approach to discovering novel inhibitors of human sirtuin type 2. J. Med. Chem. 47 (2004) 6292-6298
65. Kiviranta P.H., Leppanen J., Kyrylenko S., Salo H.S., Lahtela-Kakkonen M., Tervo A.J., Wittekindt C., Suuronen T., Kuusisto E., Jarvinen T., Salminen A., Poso A., and Wallen E.A. N,N′-Bisbenzylidenebenzene-1,4-diamines and N,N′-bisbenzylidenenaphthalene-1,4-diamines as sirtuin type 2 (SIRT2) inhibitors. J. Med. Chem. 49 (2006) 7907-7911
66. Tervo A.J., Suuronen T., Kyrylenko S., Kuusisto E., Kiviranta P.H., Salminen A., Leppanen J., and Poso A. Discovering inhibitors of human sirtuin type 2: novel structural scaffolds. J. Med. Chem. 49 (2006) 7239-7241
67. Gey C., Kyrylenko S., Hennig L., Nguyen L.H., Buttner A., Pham H.D., and Giannis A. Phloroglucinol derivatives guttiferone G, aristoforin, and hyperforin: inhibitors of human sirtuins SIRT1 and SIRT2. Angew. Chem., Int. Ed. Engl. 46 (2007) 5219-5222
68. Schäfer S., Saunders L., Eliseeva E.D., Velena A., Jung M., Schwienhorst A., Strasser A., Dickmanns A., Ficner R., Schlimme S., Sippl W., Verdin E., and Jung M. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Bioorg. Med. Chem. 16 (2008) 2011-2033
69. Ota H., Tokunaga E., Chang K., Hikasa M., Iijima K., Eto M., Kozaki K., Akishita M., Ouchi Y., and Kaneki M. Sirt1 inhibitor, sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25 (2006) 176-185